ReviveMed Announces AI-driven Metabolomics Study with Bristol Myers Squibb
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ReviveMed is proud to announce that they are pursuing an evaluation study with Bristol Myers Squibb (NYSE: BMY). This study will leverage ReviveMed’s artificial intelligence (AI) platform to better understand mechanisms of response and resistance to immunotherapies in patients with cancer.“We are very excited about this opportunity to work alongside industry leaders on the Bristol Myers Squibb team,” said Dr. Leila Pirhaji, ReviveMed’s Founder and CEO. “We are looking forward to discovering new biological insights through the use of artificial intelligence to characterize a large number of metabolites and integrate these data with other molecular datasets such as proteomics and genomics.”There is growing evidence of metabolites’ role as regulators of biological activities and modifiers of other omics, including genomics. ReviveMed has built one of the most comprehensive databases about metabolites and their interactions with other molecules. Thei
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung… [YahoYaho
- Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…Business Wire
- Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s DiseaseBusiness Wire
- Home Depot Eyes $12.5 Billion Debt Package to Fund SRS Merger [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 2/2/24 - Beat
BMY
Sec Filings
- 3/18/24 - Form 8-K
- 3/18/24 - Form PRE
- 3/18/24 - Form 8-K
- BMY's page on the SEC website